Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/111153
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10 |
Autor: | Gallego, Oriol; Ruiz, Francesc Xavier; Ardèvol, Albert; Domínguez, Marta CSIC; Álvarez, Rosana; Lera, Ángel R. de; Rovira, Carme; Farrés, Jaume; Fita, Ignacio CSIC ORCID ; Parés, Xavier | Palabras clave: | Protein structure Retinoic acid Tolrestat Aldo-keto reductases Aldose reductase |
Fecha de publicación: | 26-dic-2007 | Editor: | National Academy of Sciences (U.S.) | Citación: | Proceedings of the National Academy of Sciences of the United States of America 104(52): 20764-20769 (2007) | Resumen: | AKR1B10 is a human aldo-keto reductase (AKR) found to be elevated in several cancer types and in precancerous lesions. In vitro, AKR1B10 exhibits a much higher retinaldehyde reductase activity than any other human AKR, including AKR1B1 (aldose reductase). We here demonstrate that AKR1B10 also acts as a retinaldehyde reductase in vivo. This activity may be relevant in controlling the first step of retinoic acid synthesis. Up-regulation of AKR1B10, resulting in retinoic acid depletion, may lead to cellular proliferation. Both in vitro and in vivo activities of AKR1B10 were inhibited by tolrestat, an AKR1B1 inhibitor developed for diabetes treatment. The crystal structure of the ternary complex AKR1B10-NADP+-tolrestat was determined at 1.25-Å resolution. Molecular dynamics models of AKR1B10 and AKR1B1 with retinaldehyde isomers and site-directed mutagenesis show that subtle differences at the entrance of the retinoid-binding site, especially at position 125, are determinant for the all-trans-retinaldehyde specificity of AKR1B10. Substitutions in the retinaldehyde cyclohexene ring also influence the specificity. These structural features should facilitate the design of specific inhibitors, with potential use in cancer and diabetes treatments. © 2007 by The National Academy of Sciences of the USA. | Versión del editor: | http://dx.doi.org/10.1073/pnas.0705659105 | URI: | http://hdl.handle.net/10261/111153 | DOI: | 10.1073/pnas.0705659105 | Identificadores: | doi: 10.1073/pnas.0705659105 issn: 0027-8424 |
Aparece en las colecciones: | (IBMB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
70
checked on 15-abr-2024
SCOPUSTM
Citations
157
checked on 16-abr-2024
WEB OF SCIENCETM
Citations
152
checked on 29-feb-2024
Page view(s)
319
checked on 18-abr-2024
Download(s)
105
checked on 18-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.